Index Entries

Colleen Huber
July 14, 2021
Primary Doctor Medical Journal

Discussion: The pathways discussed herein are inevitable routes of spike protein transit in the body and in the cells. ACE2 receptors are abundant in every known cell type. When spike proteins have been introduced to the body, either through the SARS-CoV-2 virus or by means of the mRNA COVID vaccines, is there any realistic way possible to block their interaction with ACE2 receptors in any individual? In the case of acute infection with SARS-CoV-2, infected individuals have a self-limiting encounter with spike proteins, which may be thwarted by some of the therapeutics mentioned above. However, in the case of the mRNA-vaccinated, no endpoint of spike protein production is yet known. Nor is it yet known if it is safe to use any of the spike protein blocking therapeutics in vaccinated individuals.

In the absence of extraordinary and deliberate measures to block ACE2 receptors and CD147 receptors and/or Caspase 3/7 activity, is it then possible to expect that cardiac pericytes and endothelial cells could escape the pro-inflammatory and pro-apoptotic effects of the spike protein, especially considering that protein’s perpetual regeneration in vaccinated people? Could a therapeutic be invented for vaccinated people to protect their cardiomyocytes and pericytes from spike protein damage, and to be dosed frequently enough to combat the body’s ongoing spike protein production? If such an expectation is not realistic, then mRNA vaccines that prepare human cells to generate an unknown supply of spike proteins for an unknown amount of time are to be treated with extreme caution and avoidance until better understood. It is also necessary to defer further vaccination until there are known methods of both discharge of such proteins and the mechanism to turn off or attenuate mRNA-induced spike proteins, and/or to safely thwart the destructive effects of spike proteins in host cells.”

document
adverse events,COVID-19,heart disorders,vaccines